Extracellular vesicle markers in relation to obesity and metabolic complications in patients with manifest cardiovascular disease

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Kranendonk, Mariëtte E G ^a   de Kleijn, Dominique P V ^a,b   Kalkhoven, Eric ^a   Kanhai, Danny A ^a   Uiterwaal, Cuno S P M ^a   van der Graaf, Yolanda ^a   Pasterkamp, Gerard ^a   Visseren, Frank L J ^a   Doevendans, P A ^a   Algra, A ^a   Grobbee, D E ^a   Rutten, G E H M ^a   Kappelle, L J ^a   Mali, W P T M ^a   Moll, F L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Extracellular vesicle markers; hsCRP; Metabolic syndrome; Obesity; Type 2 diabetes

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CD14 ANTIGEN; CYSTATIN C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SERINE PROTEINASE INHIBITOR; SERPIN F2; SERPIN G1; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CELL VACUOLE; DISEASE ASSOCIATION; EXTRACELLULAR VESICLE; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RISK FACTOR; SUBCUTANEOUS FAT;

ADIPOSE TISSUE; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CELL-DERIVED MICROPARTICLES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; EXOSOMES; EXTRACELLULAR FLUID; FOLLOW-UP STUDIES; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84893192136     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-37     Document Type: Article

References (49)

1. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008, 29(24):2959-2971. 10.1093/eurheartj/ehn387, 18775919.
2. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P, Razak F, Sharma AM, Anand SS, INTERHEART Study Investigators Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005, 366(9497):1640-1649. 10.1016/S0140-6736(05)67663-5, 16271645, INTERHEART Study Investigators.
3. Nicklas BJ, Penninx BW, Cesari M, Kritchevsky SB, Newman AB, Kanaya AM, Pahor M, Jingzhong D, Harris TB, Health, Aging and Body Composition Study Association of visceral adipose tissue with incident myocardial infarction in older men and women: the Health, Aging and Body Composition Study. Am J Epidemiol 2004, 160(8):741-749. 10.1093/aje/kwh281, 15466496, Health, Aging and Body Composition Study.
4. Kanhai DA, Kappelle LJ, van der Graaf Y, Uiterwaal CS, Visseren FL, SMART Study Group The risk of general and abdominal adiposity in the occurrence of new vascular events and mortality in patients with various manifestations of vascular disease. Int J Obes (Lond) 2012, 36(5):695-702. 10.1038/ijo.2011.115, 21712810, SMART Study Group.
5. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112(12):1821-1830. 10.1172/JCI200319451, 296998, 14679177.
6. Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, Wabitsch M, Fischer-Posovszky P, Barth TF, Dragun D, Skurk T, Hauner H, Bluher M, Unger T, Wolf AM, Knippschild U, Hombach V, Marx N. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol 2008, 28(7):1304-1310. 10.1161/ATVBAHA.108.165100, 18420999.
7. Faber DR, van der Graaf Y, Westerink J, Visseren FL. Increased visceral adipose tissue mass is associated with increased C-reactive protein in patients with manifest vascular diseases. Atherosclerosis 2010, 212(1):274-280. 10.1016/j.atherosclerosis.2010.04.029, 20494358.
8. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002, 13(2):84-89. 10.1016/S1043-2760(01)00524-0, 11854024.
9. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010, 72:219-246. 10.1146/annurev-physiol-021909-135846, 20148674.
10. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C, American Heart Association, National Heart, Lung, and Blood Institute Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109(3):433-438. 10.1161/01.CIR.0000111245.75752.C6, 14744958, American Heart Association, National Heart, Lung, and Blood Institute.
11. Kuller LH, Velentgas P, Barzilay J, Beauchamp NJ, O'Leary DH, Savage PJ. Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arterioscler Thromb Vasc Biol 2000, 20(3):823-829. 10.1161/01.ATV.20.3.823, 10712409.
12. Karastergiou K, Smith SR, Greenberg AS, Fried SK. Sex differences in human adipose tissues - the biology of pear shape. Biol Sex Differ 2012, 3(1):13-6410. 3-13, 10.1186/2042-6410-3-13, 3411490, 22651247.
13. Musaad S, Haynes EN. Biomarkers of obesity and subsequent cardiovascular events. Epidemiol Rev 2007, 29:98-114. 10.1093/epirev/mxm005, 17494057.
14. Liu ML, Williams KJ. Microvesicles: potential markers and mediators of endothelial dysfunction. Curr Opin Endocrinol Diabetes Obes 2012, 19(2):121-127. 10.1097/MED.0b013e32835057e9, 22248645.
15. Muller G. Microvesicles/exosomes as potential novel biomarkers of metabolic diseases. Diabetes Metab Syndr Obes 2012, 5:247-282. 3422911, 22924003.
16. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009, 9(8):581-593. 10.1038/nri2567, 19498381.
17. Nolte-'t Hoen EN, Wauben MH. Immune cell-derived vesicles: modulators and mediators of inflammation. Curr Pharm Des 2012, 18(16):2357-2368. 10.2174/138161212800166013, 22390699.
18. Kanhai DA, Visseren FL, van der Graaf Y, Schoneveld AH, Catanzariti LM, Timmers L, Kappelle LJ, Uiterwaal CS, Lim SK, Sze SK, Pasterkamp G, de Kleijn DP, SMART Study Group Microvesicle protein levels are associated with increased risk for future vascular events and mortality in patients with clinically manifest vascular disease. Int J Cardiol 2013, 168(3):2358-2363. 10.1016/j.ijcard.2013.01.231, 23484740, SMART Study Group.
19. Lafarge JC, Naour N, Clement K, Guerre-Millo M. Cathepsins and cystatin C in atherosclerosis and obesity. Biochimie 2010, 92(11):1580-1586. 10.1016/j.biochi.2010.04.011, 20417681.
20. Fu Z, Xue H, Guo J, Chen L, Dong W, Gai L, Liu H, Sun Z, Chen Y. Long-term prognostic impact of cystatin c on acute coronary syndrome octogenarians with diabetes mellitus. Cardiovasc Diabetol 2013, 12(1):157. 10.1186/1475-2840-12-157, 24182196.
21. Schousboe I. Binding of activated Factor XII to endothelial cells affects its inactivation by the C1-esterase inhibitor. Eur J Biochem 2003, 270(1):111-118.
22. Collen D, Lijnen HR. The fibrinolytic system in man. Crit Rev Oncol Hematol 1986, 4(3):249-301.
23. Aharon A, Tamari T, Brenner B. Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb Haemost 2008, 100(5):878-885.
24. Fantuzzi G, Mazzone T. Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol 2007, 27(5):996-1003. 10.1161/ATVBAHA.106.131755, 17303782.
25. Rocha VZ, Folco EJ, Sukhova G, Shimizu K, Gotsman I, Vernon AH, Libby P. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res 2008, 103(5):467-476. 10.1161/CIRCRESAHA.108.177105, 2740384, 18658050.
26. Napoleone E, DI Santo A, Amore C, Baccante G, di Febbo C, Porreca E, de Gaetano G, Donati MB, Lorenzet R. Leptin induces tissue factor expression in human peripheral blood mononuclear cells: a possible link between obesity and cardiovascular risk?. J Thromb Haemost 2007, 5(7):1462-1468. 10.1111/j.1538-7836.2007.02578.x, 17425664.
27. Lorenzet R, Napoleone E, Cutrone A, Donati MB. Thrombosis and obesity: cellular bases. Thromb Res 2012, 129(3):285-289. 10.1016/j.thromres.2011.10.021, 22078462.
28. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol 1999, 15(9):773-781. 10.1023/A:1007621514757, 10608355.
29. de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003, 10(1):133-139. 145264, 12522051.
30. Stolk RP, Meijer R, Mali WP, Grobbee DE, van der Graaf Y, Secondary Manifestations of Arterial Disease Study Group Ultrasound measurements of intraabdominal fat estimate the metabolic syndrome better than do measurements of waist circumference. Am J Clin Nutr 2003, 77(4):857-860. Secondary Manifestations of Arterial Disease Study Group.
31. Schipper HS, de Jager W, van Dijk ME, Meerding J, Zelissen PM, Adan RA, Prakken BJ, Kalkhoven E. A multiplex immunoassay for human adipokine profiling. Clin Chem 2010, 56(8):1320-1328. 10.1373/clinchem.2010.146118, 20530731.
32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419. 10.1007/BF00280883, 3899825.
33. Bland JM, Altman DG. Transformations, means, and confidence intervals. BMJ 1996, 312(7038):1079. 10.1136/bmj.312.7038.1079, 2350916, 8616417.
34. Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol 2008, 121(2):326-330. 10.1016/j.jaci.2007.10.018, 18061654.
35. Muntner P, Winston J, Uribarri J, Mann D, Fox CS. Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. Am J Med 2008, 121(4):341-348. 10.1016/j.amjmed.2008.01.003, 3049932, 18374694.
36. Naour N, Fellahi S, Renucci JF, Poitou C, Rouault C, Basdevant A, Dutour A, Alessi MC, Bastard JP, Clement K, Guerre-Millo M. Potential contribution of adipose tissue to elevated serum cystatin C in human obesity. Obesity (Silver Spring) 2009, 17(12):2121-2126. 10.1038/oby.2009.96, 19360013.
37. Magnusson M, Hedblad B, Engstrom G, Persson M, Nilsson P, Melander O. High levels of cystatin C predict the metabolic syndrome: the prospective Malmo Diet and Cancer Study. J Intern Med 2013, 274(2):192-199. 10.1111/joim.12051, 23414447.
38. Sabanayagam C, Wong TY, Xiao J, Shankar A. Serum cystatin C and prediabetes in non-obese US adults. Eur J Epidemiol 2013, 28(4):311-316. 10.1007/s10654-013-9781-3, 23417728.
39. Qing X, Furong W, Yunxia L, Jian Z, Xuping W, Ling G. Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate. Cardiovasc Diabetol 2012, 11:108-2840. 11-108, 10.1186/1475-2840-11-108, 3473246, 22978689.
40. Cai S, Davis AE. 3rd: Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion. J Immunol 2003, 171(9):4786-4791.
41. Kozek E, Katra B, Malecki M, Sieradzki J. Visceral obesity and hemostatic profile in patients with type 2 diabetes: the effect of gender and metabolic compensation. Rev Diabet Stud 2004, 1(3):122-128. 10.1900/RDS.2004.1.122, 1783547, 17491674.
42. Fernandez-Real JM, Perez Del Pulgar S, Luche E, Moreno-Navarrete JM, Waget A, Serino M, Sorianello E, Sanchez-Pla A, Pontaque FC, Vendrell J, Chacon MR, Ricart W, Burcelin R, Zorzano A. CD14 modulates inflammation-driven insulin resistance. Diabetes 2011, 60(8):2179-2186. 10.2337/db10-1210, 3142089, 21700881.
43. Poitou C, Dalmas E, Renovato M, Benhamo V, Hajduch F, Abdennour M, Kahn JF, Veyrie N, Rizkalla S, Fridman WH, Sautes-Fridman C, Clement K, Cremer I. CD14dimCD16+ and CD14 + CD16+ monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2011, 31(10):2322-2330. 10.1161/ATVBAHA.111.230979, 21799175.
44. Fernandez-Real JM, Lopez-Bermejo A, Castro A, Broch M, Penarroja G, Vendrell J, Vazquez G, Ricart W. Opposite relationship between circulating soluble CD14 concentration and endothelial function in diabetic and nondiabetic subjects. Thromb Haemost 2005, 94(3):615-619.
45. Koethe JR, Dee K, Bian A, Shintani A, Turner M, Bebawy S, Sterling TR, Hulgan T. Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy. AIDS Res Hum Retroviruses 2013, 29(7):1019-1025. 10.1089/aid.2013.0016, 23469772.
46. Kirkland TN, Viriyakosol S. Structure-function analysis of soluble and membrane-bound CD14. Prog Clin Biol Res 1998, 397:79-87.
47. Yin W, Ghebrehiwet B, Peerschke EI. Expression of complement components and inhibitors on platelet microparticles. Platelets 2008, 19(3):225-233. 10.1080/09537100701777311, 2659880, 18432523.
48. Deng ZB, Poliakov A, Hardy RW, Clements R, Liu C, Liu Y, Wang J, Xiang X, Zhang S, Zhuang X, Shah SV, Sun D, Michalek S, Grizzle WE, Garvey T, Mobley J, Zhang HG. Adipose tissue exosome-like vesicles mediate activation of macrophage-induced insulin resistance. Diabetes 2009, 58(11):2498-2505. 10.2337/db09-0216, 2768161, 19675137.
49. Kranendonk ME, Visseren FL, van Balkom BW, Hoen EN, van Herwaarden JA, de Jager W, Schipper HS, Brenkman AB, Verhaar MC, Wauben MH, Kalkhoven E. Human adipocyte extracellular vesicles in reciprocal signaling between adipocytes and macrophages Human adipocyte EVs and macrophages. Obesity (Silver Spring) 2013, 10.1002/oby.20679.